GenVisc 850 Injection Cost: $400–$700 Per Course (2026 Guide)

Q: What are the CPT and HCPCS billing codes for GenVisc 850?

GenVisc 850 involves two billing codes that appear together on a single claim: HCPCS J7320 — Hyaluronan or derivative, GenVisc 850, for intra-articular injection, 1 mg (covers the medication; providers typically bill 25 units per injection for the standard 25 mg/2.5 mL syringe) CPT 20610 — Arthrocentesis, aspiration and/or injection, major joint, without ultrasound guidance (covers the injection procedure when performed without imaging) CPT 20611 — Arthrocentesis, aspiration and/or injection, major joint, with ultrasound guidance and permanent recording (when imaging guidance is used) Both J7320 and one procedure code (20610 or 20611) are billed at each injection visit. If you're reviewing an Explanation of Benefits (EOB) or verifying benefits in advance, look for both codes and confirm coverage for each.

Key Takeaways

A full GenVisc 850 treatment course (3–5 weekly injections) costs $400–$700 self-pay — one of the lowest price points among FDA-approved hyaluronic acid brands
With Medicare Part B, patients typically pay 20% coinsurance after the annual deductible: roughly $75–$175 for a complete course depending on course length and whether imaging guidance is used
GenVisc 850 is billed under HCPCS code J7320 for the medication; the injection procedure is billed separately under CPT 20610 (without imaging) or CPT 20611 (with imaging guidance)
Manufactured by OrthogenRx, a subsidiary of Avanos Medical, and produced by bacterial fermentation — not avian-derived — making it safe for patients with bird, egg, or poultry allergies
Medicare covers GenVisc 850 through local coverage determinations (LCDs) issued by regional Medicare Administrative Contractors (MACs) — there is no single national coverage determination (NCD) for sodium hyaluronate
Most private insurance plans cover GenVisc 850 when medical necessity criteria are met, though prior authorization is nearly always required
GenVisc 850 uses the same active ingredient (sodium hyaluronate) as Hyalgan and Supartz FX but is generally priced lower and carries no avian-allergy risk

GenVisc 850 is a hyaluronic acid knee injection that stands out for one reason many patients care about most: cost. It uses the same active ingredient as some of the most established brands on the market, it’s covered by Medicare Part B, and it typically comes in at the lower end of the self-pay price spectrum for viscosupplementation. If you’re weighing treatment options for knee osteoarthritis, this guide breaks down exactly what you can expect to pay in 2026 — with Medicare, private insurance, and without any coverage.

What Is GenVisc 850 and Why It Costs What It Does

GenVisc 850 is a viscosupplementation injection for knee osteoarthritis manufactured by OrthogenRx, a company acquired by Avanos Medical (formerly Halyard Health) in 2019. Each 2.5 mL syringe delivers 25 mg of sodium hyaluronate — the same active molecule your knee joint produces naturally as a lubricant and shock absorber. In a healthy knee, hyaluronic acid gives joint fluid its thick, cushioning properties. Osteoarthritis degrades both the concentration and quality of this fluid; GenVisc 850 replenishes it.

The “850” in the product name refers to its molecular weight of 850 kDa (kilodaltons), placing it in the medium-molecular-weight range. The treatment is administered as a series of 3 or 5 weekly injections, with your doctor determining the appropriate course length based on your knee condition and treatment response.

Several factors explain why GenVisc 850 is priced at the lower end of the hyaluronic acid market:

Non-proprietary active ingredient: Sodium hyaluronate is the same molecule found in Hyalgan, Supartz FX, and other established brands. GenVisc 850 does not rely on a proprietary cross-linking process or unique formulation, which reduces production complexity and licensing costs
Biofermentation instead of avian extraction: GenVisc 850 is produced through bacterial fermentation, not extracted from rooster combs (avian sources). This process is efficient, allergy-free, and does not require the sourcing and processing of animal tissue
Less consumer advertising spend: Unlike premium single-injection brands with major TV and print campaigns, GenVisc 850 carries minimal direct-to-consumer marketing costs — savings that can translate to lower provider pricing
Competitive market positioning: OrthogenRx designed GenVisc 850 specifically as a cost-competitive option for the Medicare market, where formulary review boards and step-therapy protocols favor lower-cost alternatives
Per-injection price spread: Because the treatment requires 3–5 office visits rather than concentrating everything into a single premium vial, the medication cost per syringe is naturally lower than single-injection brands

GenVisc 850 Cost Without Insurance (Self-Pay)

Self-Pay Price Ranges for GenVisc 850 (2026)

Cost Component	Range
Medication only — 3-injection course	$250–$480
Medication only — 5-injection course	$350–$600
Office visit fee per injection (if billed separately)	$50–$150
Imaging guidance per visit (if used and billed separately)	$100–$300
Total self-pay — 3-injection course (all-in)	$400–$600
Total self-pay — 5-injection course (all-in)	$450–$700

Why Self-Pay Prices Vary So Much

The same GenVisc 850 series can cost dramatically different amounts depending on where and how it’s provided:

Provider type and setting: Office-based orthopedic practices and pain management clinics typically charge less than hospital outpatient departments, which add a facility fee on top of physician and drug costs
Geographic location: Urban markets and high cost-of-living regions charge more; rural providers often price lower to compete for patients
Bundled vs. unbundled billing: Some providers include the office visit and medication in a single “injection visit” fee; others bill each component separately, making direct price comparison difficult
Provider markup: Clinics purchase GenVisc 850 from distributors at wholesale pricing and apply their own markup — margins vary considerably by practice type and size
Discount programs: Tools like GoodRx and SingleCare can reduce the out-of-pocket cost for the medication component; availability for physician-administered J-code products varies by platform and pharmacy vs. buy-and-bill context

Tip: When calling providers, ask for their “self-pay price for a complete GenVisc 850 series” and confirm whether the quote includes the office visit, medication, and imaging guidance — or how each is billed separately. Comparing 2–3 local providers can save $100–$200 on the full course.

GenVisc 850 Cost With Medicare Part B

Medicare Coverage for GenVisc 850

Coverage status: Yes — Medicare Part B covers GenVisc 850 (J7320) for knee osteoarthritis

Typical patient cost with Medicare:

Annual Part B deductible: $257 (2025; verify the current year at Medicare.gov)
After deductible: You pay 20% coinsurance of the Medicare-approved amount
Medicare pays the remaining 80% of the approved amount

Estimated patient out-of-pocket (deductible already met):

3-injection course: approximately $75–$110
5-injection course: approximately $110–$175
If deductible not yet met: add up to $257 before coinsurance begins

How Medicare Bills GenVisc 850

Medicare uses HCPCS code J7320 for GenVisc 850 (Hyaluronan or derivative, GenVisc 850, for intra-articular injection, 1 mg). Each standard 2.5 mL syringe contains 25 mg of sodium hyaluronate, so providers bill 25 units of J7320 per injection visit.

Medicare’s Part B drug payment is based on the Average Sales Price (ASP) methodology published quarterly by CMS. The ASP for J7320 is approximately $0.74 per unit (per mg), giving a total ASP for one injection of approximately $18.50 (25 mg × $0.74). Medicare reimburses providers at ASP+6%, or approximately $19.61 per injection for the drug component alone. Your 20% patient share of the drug is approximately $3.92 per injection.

The injection procedure itself is billed separately on the same claim under:

CPT 20610 — Arthrocentesis/injection of a major joint, without imaging guidance. Medicare-allowed amount: approximately $80–$105, depending on geographic locality; your 20% = approximately $16–$21 per visit
CPT 20611 — Arthrocentesis/injection of a major joint, with ultrasound or fluoroscopy guidance and permanent recording. Medicare-allowed amount: approximately $120–$150; your 20% = approximately $24–$30 per visit

Full course math (5 injections, unguided, deductible met):

Drug coinsurance: 5 × $3.92 = ~$19.60
Procedure coinsurance: 5 × ~$18 = ~$90
Total estimated out-of-pocket: approximately $110 — before any Medigap or supplemental coverage applies

CMS rates update quarterly. Always verify current ASP pricing at the CMS Part B Drug ASP Pricing page or ask your provider for the current Medicare-approved amount before scheduling.

Medicare Coverage Requirements

Unlike some medications covered by a single national policy, Medicare covers sodium hyaluronate products including GenVisc 850 through local coverage determinations (LCDs) issued by regional Medicare Administrative Contractors (MACs). This means coverage criteria can vary by region. Most LCDs for sodium hyaluronate products require similar documentation:

Confirmed diagnosis of knee osteoarthritis, typically supported by X-ray imaging documenting disease severity

Documentation that conservative treatments have been tried without adequate relief — typically including physical therapy, oral NSAIDs or analgesics, and weight management where applicable

Treatment performed by a qualified provider (orthopedic surgeon, physiatrist, primary care physician, or other credentialed provider performing intra-articular injections)

Repeat treatment courses spaced at least 6 months apart from the previous course

Find your MAC’s LCD: Because sodium hyaluronate coverage is governed by local determinations, your specific MAC may have additional or slightly different documentation requirements. Search the applicable LCD at the CMS Medicare Coverage Database using your state or MAC name.

Medicare Advantage Plans

If you have a Medicare Advantage (Part C) plan rather than Original Medicare, GenVisc 850 coverage may differ. Medicare Advantage plans are required to cover all services covered by Original Medicare, but they may impose:

Prior authorization requirements before the injection series begins
Network restrictions limiting which providers can administer covered injections
Different cost-sharing — your plan may use fixed copays per visit rather than 20% coinsurance, which can be higher or lower than Original Medicare’s structure
Step therapy requirements mandating documentation of failed conservative treatment before approving HA injections

Always verify coverage, prior authorization requirements, and network status with your specific Medicare Advantage plan before scheduling your first injection.

GenVisc 850 Cost With Private Insurance

Most commercial health insurance plans cover GenVisc 850 for knee osteoarthritis when medical necessity criteria are met, similar in structure to Medicare requirements — though the process is more variable by plan.

Typical private insurance process:

Prior authorization is nearly always required — your provider’s office typically submits this on your behalf before scheduling begins
Step therapy is common — many plans require documentation that physical therapy and/or oral medications were tried before approving injections
Copay or coinsurance: Varies significantly by plan — typically $100–$300 for the full series after meeting the deductible
Deductible: If your deductible has not been met, you may be responsible for the full allowed amount per visit until it is

Tip: Ask your provider’s office to obtain prior authorization and verify your exact benefits — including whether GenVisc 850 (J7320) is a covered benefit and whether any step-therapy requirements apply — before your first appointment. Get the authorization number in writing before proceeding.

GenVisc 850’s positioning as a lower-cost HA option can work in your favor with private insurers. Many commercial plans use step therapy protocols requiring patients to complete a course of a lower-cost HA product before approving a more expensive brand like Synvisc-One. GenVisc 850 often qualifies as a first-line HA product under these protocols, making coverage approval more straightforward than for premium alternatives.

GenVisc 850 vs. Other Multi-Injection Series: Cost Comparison

GenVisc 850 belongs to the multi-injection series category of FDA-approved HA products. Here’s how it stacks up against other brands in the same category:

Brand	Injections	HCPCS	Source	Self-Pay (Full Course)	Bird-Allergy Safe	Medicare Covered
GenVisc 850	3–5	J7320	Non-avian (biofermented)	$400–$700	Yes	Yes
Hyalgan	3–5	J7321	Avian (rooster comb)	$500–$900	No	Yes
Supartz FX	3–5	J7321	Avian (rooster comb)	$500–$900	No	Yes
Euflexxa	3	J7323	Non-avian (biofermented)	$700–$1,100	Yes	Yes
Orthovisc	3–4	J7324	Non-avian (biofermented)	$600–$1,000	Yes	Yes

Key observations:

GenVisc 850 is typically one of the lowest-priced multi-injection series options for self-pay patients
Hyalgan and Supartz FX share the J7321 billing code and are avian-derived — not safe for patients with bird, egg, or poultry allergies
Euflexxa is also non-avian and requires only 3 injections, but generally costs $300–$400 more per course at self-pay rates
All brands in this table are covered by Medicare Part B under their respective HCPCS codes when medical necessity criteria are met

GenVisc 850 vs. Single-Injection Brands: True Cost Comparison

Single-injection products require only one office visit, while GenVisc 850 requires 3–5 weekly trips. The medication sticker price for a single-injection brand looks higher, but the total cost comparison is more nuanced once you factor in visit copays and time commitment.

	GenVisc 850	Synvisc-One	Gel-One	Monovisc	Durolane
Injections needed	3–5	1	1	1	1
HCPCS code	J7320	J7325	J7326	J7327	J7318
Source	Non-avian	Avian	Avian	Non-avian	Non-avian
Self-pay (full treatment)	$400–$700	$600–$1,200	$400–$900	$500–$1,000	$300–$1,465
Office visit copays	3–5×	1×	1×	1×	1×
Time commitment	3–5 weeks	1 visit	1 visit	1 visit	1 visit
Bird-allergy safe	Yes	No	No	Yes	Yes

The visit-copay math matters for Medicare patients. With a $20 copay per visit, a 5-injection GenVisc 850 course adds $100 in copays vs. $20 for a single-injection brand — a $80 disadvantage. However, the medication cost for GenVisc 850 is typically $200–$500 less per course than single-injection alternatives, more than offsetting the extra visit copays for most patients.

Step therapy consideration: Some private insurers require completion of a lower-cost multi-injection series — often GenVisc 850 or Hyalgan — before approving a premium single-injection brand. Completing a GenVisc 850 course may satisfy this requirement, paving the way for a future single-injection approval if a different product is preferred.

Hidden Costs to Budget For

When planning for a GenVisc 850 series, account for these additional expenses beyond the medication cost itself:

Frequently Overlooked Costs

Multiple office visit fees (3–5 visits): Each injection visit may carry a separate office visit fee or copay — $20–$60 per visit for Medicare, $50–$150 for self-pay. Across a 5-injection course, this adds $100–$750 to the total, compared to a single copay for one-injection brands

Imaging guidance at each visit: If your provider uses ultrasound or fluoroscopy guidance to ensure accurate placement (CPT 20611), this is billed at every injection appointment. Without insurance, imaging guidance can add $100–$300 per visit — up to $1,500 over a 5-injection course. Medicare covers imaging guidance at higher reimbursement but adds to your 20% coinsurance

Pre-injection knee X-rays: If you don’t have recent imaging documenting your osteoarthritis, your provider may require X-rays ($100–$300 without insurance) before beginning the series to satisfy Medicare or insurance documentation requirements

Facility fees at hospital outpatient departments: If your injections are performed in a hospital outpatient setting rather than an office-based clinic, you may be billed a hospital facility fee of $200–$500+ per visit in addition to physician and drug fees — which can substantially inflate costs across a 5-injection course

Follow-up visit: Many providers schedule a 4–6 week post-series appointment to assess your response and document outcomes for future treatment authorization

How to Reduce Your Out-of-Pocket Costs

For Medicare Patients

Enroll in a Medigap (supplement) plan: A Medicare Supplement policy covers most or all of the 20% Part B coinsurance, potentially reducing your total cost for a GenVisc 850 series to near $0 beyond your monthly premium

Time your treatment before year-end: If you’ve already met your annual Part B deductible, schedule before December 31 to avoid restarting the deductible in January on a multi-week injection series

Choose office-based providers over hospital outpatient: Hospital outpatient departments add a facility fee that office-based clinics do not charge — for a 5-injection series, this choice alone can save $1,000–$2,500 even with Medicare

Verify your MAC’s LCD documentation requirements in advance: Ask your provider to confirm that your chart documentation satisfies your regional Medicare Administrative Contractor’s local coverage determination for J7320 before your first injection — catching documentation gaps early prevents claim denials

For Self-Pay Patients

Ask explicitly for the cash/self-pay rate: Many clinics offer discounted rates for patients not billing insurance — ask for the “self-pay price for the full GenVisc 850 series” and confirm whether it includes office visits and medication

Use prescription discount programs: GoodRx and SingleCare may reduce the medication component cost — check both platforms for current pricing in your ZIP code before your appointment

Ask about Avanos patient support programs: Contact Avanos Medical (GenVisc 850’s parent company) directly to inquire about any available patient assistance or financial support programs

Compare 2–3 local providers: Self-pay rates for the same product vary significantly across clinics in the same city — a few phone calls requesting the self-pay rate for a GenVisc 850 series can identify meaningful cost differences

Frequently Asked Questions

Does Medicare cover GenVisc 850 injections?

Yes. Medicare Part B covers GenVisc 850 (billed as HCPCS J7320) for knee osteoarthritis when medical necessity criteria are met. Coverage is governed by local coverage determinations (LCDs) issued by regional Medicare Administrative Contractors — not a single national coverage policy — so specific documentation requirements can vary slightly by region. After meeting your annual Part B deductible ($257 in 2025), you typically pay 20% coinsurance. For a full 3–5 injection course (deductible met), total patient out-of-pocket is generally $75–$175, depending on course length and whether imaging guidance is billed.

How much does GenVisc 850 cost without insurance?

Without insurance, a complete GenVisc 850 treatment course typically costs $400–$700, including both the medication and office visit fees. A 3-injection course runs approximately $400–$600; a 5-injection course approximately $450–$700. Prices vary by provider, location, and whether imaging guidance is bundled or billed separately. Calling multiple local providers and asking for their self-pay rate is the most reliable way to find the best price in your area.

What are the CPT and HCPCS billing codes for GenVisc 850?

GenVisc 850 involves two billing codes that appear together on a single claim:

HCPCS J7320 — Hyaluronan or derivative, GenVisc 850, for intra-articular injection, 1 mg (covers the medication; providers typically bill 25 units per injection for the standard 25 mg/2.5 mL syringe)
CPT 20610 — Arthrocentesis, aspiration and/or injection, major joint, without ultrasound guidance (covers the injection procedure when performed without imaging)
CPT 20611 — Arthrocentesis, aspiration and/or injection, major joint, with ultrasound guidance and permanent recording (when imaging guidance is used)

Both J7320 and one procedure code (20610 or 20611) are billed at each injection visit. If you’re reviewing an Explanation of Benefits (EOB) or verifying benefits in advance, look for both codes and confirm coverage for each.

Is GenVisc 850 safe for patients with bird or egg allergies?

Yes. This is one of GenVisc 850’s most clinically significant advantages. It is produced through bacterial fermentation (biofermentation) — it is not derived from avian sources such as rooster combs. Patients with allergies to birds, eggs, poultry, or feathers can safely receive GenVisc 850. By contrast, avian-derived products such as Hyalgan, Supartz FX, Synvisc-One, and Gel-One carry specific contraindications for patients with these allergies. If you have a bird or egg allergy, GenVisc 850 and other biofermented products (Euflexxa, Monovisc, Durolane) are the appropriate options to discuss with your doctor.

How often can I repeat GenVisc 850 treatment and what does that cost annually?

Medicare allows repeat GenVisc 850 treatment no sooner than 6 months after a prior course when the previous treatment was effective. Most patients can therefore receive up to two courses per year. Annual cost with Original Medicare (20% coinsurance, deductible already met) is typically $150–$350 for two courses. Self-pay patients would pay approximately $800–$1,400 annually for two full 5-injection courses.

Does GenVisc 850 require prior authorization?

Original Medicare does not require prior authorization for GenVisc 850, but your provider must document medical necessity that satisfies your MAC’s local coverage determination criteria before billing. Medicare Advantage and private insurance plans almost universally require prior authorization. Failure to obtain authorization before treatment can result in a denied claim — leaving you fully responsible for the cost. A reputable clinic handles prior authorization proactively before scheduling your first injection; always confirm authorization is in place before proceeding.

How does GenVisc 850 compare in cost to Hyalgan?

GenVisc 850 and Hyalgan are pharmacologically very similar — both are sodium hyaluronate, both require 3–5 weekly injections, and both are FDA-cleared for knee osteoarthritis. Key differences: GenVisc 850 is produced by biofermentation (non-avian; safe for bird/egg allergies) while Hyalgan is avian-derived; they use different Medicare billing codes (J7320 vs. J7321); and GenVisc 850 is generally priced $100–$200 lower per full course at self-pay rates. For Medicare patients, the out-of-pocket cost difference is smaller since both are reimbursed at their respective ASP-based rates, but GenVisc 850 offers the added advantage of being allergy-safe — with no cost premium for that attribute.

Get Help Understanding GenVisc 850 Coverage

Join thousands of patients who've used our guides to navigate knee injection costs and insurance coverage.

Join 10,000+ readers. No spam.

Last updated: March 2026. Pricing reflects 2026 market data and is subject to change. Medicare ASP rates are updated quarterly by CMS — see CMS Part B Drug ASP Pricing for current J7320 figures. Always verify costs with your specific provider and insurance plan before scheduling.

Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Consult your healthcare provider to determine whether GenVisc 850 is appropriate for your condition, and verify current coverage and out-of-pocket costs with your insurance plan before beginning treatment.